Want to stay updated on the latest news?
Create a Reader Account today to follow the industries and companies that interest you, and customize your news dashboard. SIGN INTO READER ACCOUNT CREATE READER ACCOUNT
CytoSorbents Highlights New Clinical Data from Current Studies at the Live 42nd International Symposium on Intensive Care & Emergency Medicine (ISICEM)
March 22, 2023 08:09 ET
|
CytoSorbents
PRINCETON, N.J., March 22, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery...
BioAegis Therapeutics Announces Publication of a Compassionate Use Case Study of a Critical COVID-19 Patient
August 27, 2021 12:46 ET
|
BioAegis Therapeutics
Gelsolin immunomodulator treatment associated with patient’s rapid recovery. NORTH BRUNSWICK, N.J., Aug. 27, 2021 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical stage, private company...
The immunocytokines market is estimated to be worth around USD 5.4 billion by 2030, claims Roots Analysis
June 30, 2021 10:55 ET
|
Roots Analysis
London, June 30, 2021 (GLOBE NEWSWIRE) -- Roots Analysis has announced the addition of the “Immunocytokines Market, 2021-2030” report to its list of offerings. These engineered...
Study Identifies New Role of BioAegis’ ‘Inflammation Regulator’ Gelsolin Relevant for a Range of Inflammatory Diseases
April 08, 2021 18:58 ET
|
BioAegis Therapeutics
Gelsolin mitigates vascular damage by preventing release of IL-1β microparticles after trauma of high pressure and decompression. Gelsolin is non-immunosuppressive unlike current treatments to quell...
Orion Biotechnology Receives Funding to Test OB-002 for Treatment of COVID-19
July 30, 2020 10:51 ET
|
Orion Biotechnology Canada Ltd.
Ottawa, Canada, July 30, 2020 (GLOBE NEWSWIRE) -- Orion Biotechnology Canada Ltd., a clinical stage pharmaceutical company focused on precision engineering small protein therapeutics, today...
ORION BIOTECHNOLOGY SUCCESSFULLY COMPLETES PHASE I CLINICAL STUDY OF 0B-002H TOPICAL GEL FOR HIV PREVENTION
April 30, 2020 13:21 ET
|
Orion Biotechnology Canada Ltd.
Ottawa, Canada, April 30, 2020 (GLOBE NEWSWIRE) -- Orion Biotechnology Canada Ltd., a clinical stage pharmaceutical company focused on precision engineering small protein therapeutics, today...
Gene Therapy Market is Likely to grow at the CAGR of 33.3% from 2017 to 2023
February 28, 2019 08:01 ET
|
Allied Market Research
Portland, OR, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Allied Market Research published a report, titled, Gene Therapy Market by Vector Type (Viral Vector and Non-viral Vector), Gene Type (Antigen,...
Hemispherx Biopharma Announces New Publication Enlarges the Understanding of Ampligen(R) Safety Profile Across Diverse Animal Species and Focuses on the Unique TLR-3 Receptor/Ampligen(R) Interaction
April 08, 2014 08:30 ET
|
AIM ImmunoTech Inc.
PHILADELPHIA, April 8, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE:HEB) (the "Company" or "Hemispherx") announced today the peer-reviewed publication titled "Discordant Biological and...
Vista Partners Initiates Coverage on CytoSorbents Corporation (OTCQB: CTSO); $0.50 Price Target
January 29, 2014 09:00 ET
|
Vista Partners LLC
SAN FRANCISCO, CA--(Marketwired - Jan 29, 2014) - Vista Partners announced today that it has initiated coverage on CytoSorbents Corporation (OTCQB: CTSO) ("The Company," or "CTSO"); with a twelve...